Conditions: Non Small Cell Lung Cancer ROS1 Proto Oncogene Crizotinib
Keywords: Non small cell lung cancer NSCLC ROS1 ROS1 positive ROS1 proto oncogene c ros tyrosine kinases ROS1 positive NSCLC ROS1 lung cancer ALK negative Lung Carcinoma Neoplasm Crizotinib Xalkori Previously treated or untreated North East Asian
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 129
Healthy volunteers: no

Brief summary:
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation (translocation or inversion) and confirmed negative for an ALK mutation

Detailed description:

Arms:
arm 1: Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib

Interventions: intervention 1: Crizotinib
Intervention descriptions: intervention 1: None

Protocol document: